Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean pyridin and folic acid and ginger and calcium?
Displaying drugs 676 - 700 of 15294 in total

Lemborexant

Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits,...
Approved
Investigational
Matched Description: … receptors, lemborexant and other orexin antagonists (e.g. ... receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and ... potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and …
Matched Categories: … Hypnotics and Sedatives ... Sleep Initiation and Maintenance Disorders …

Erythrityl tetranitrate

A vasodilator with general properties similar to nitroglycerin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)
Approved
Experimental
Investigational

Ethambutol

Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis. Ethambutol was granted FDA...
Approved
Matched Description: … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and …
Matched Categories: … ethambutol and isoniazid ... rifampicin, ethambutol and isoniazid ... rifampicin, pyrazinamide, ethambutol and isoniazid …

Penbutolol

Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the...
Approved
Investigational
Matched Description: … Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker ... degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity. ... Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third …
Matched Categories: … penbutolol and other diuretics …

Velaglucerase alfa

Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
Approved
Investigational
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Clonazepam

A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being...
Approved
Illicit
Matched Description: … F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid ... benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and ... , however, like most benzodiazepines, clonazepam use has also been associated with recreational use and …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …

Nintedanib

Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one...
Approved
Matched Description: … used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and ... agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and ... indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Trypsin

Trypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals. When converted from its zymogen trypsinogen, trypsin is available as an active peptide hydrolase (EC 3.4.21.4) form to cleave peptide chains, mainly at the carboxyl side of the amino acids lysine or arginine....
Approved
Vet approved
Matched Description: … Trypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals ... Therapeutic forms of trypsin is obtained from purified extracts of porcine or bovine pancreas and is ... nucleophilic attack is facilitated by the catalytic triad consisting of histidine-57, aspartate-102, and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Preparations for Treatment of Wounds and Ulcers …

Cisatracurium

Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.[A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597]. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is...
Approved
Investigational
Matched Description: … [A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly ... [A243416,A253592] Cisatracurium is an R-cis-R-cis isomer of [atracurium] and has approximately 3 times …

Tirzepatide

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials....
Approved
Investigational
Matched Description: … [A246260] Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty ... agonists in preclinical and clinical trials. ... only GIP and GLP-1 receptor agonist for this indication. …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Nabumetone

Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree...
Approved
Matched Description: … Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval ... [label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Beremagene geperpavec

Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy. Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). DEB is caused by mutations in the COL7A1 gene that...
Approved
Matched Categories: … Cellular and Gene Therapy ... Preparations for Treatment of Wounds and Ulcers …

Axitinib

Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation...
Approved
Investigational
Matched Description: … [L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. ... [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations. …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …

Agalsidase alfa

Agalsidase alfa is a recombinant human α-galactosidase A similar to agalsidase beta. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Octreotide

Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is...
Approved
Investigational
Matched Description: … Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also ... , including carcinoid tumors and vasoactive intestinal tumors (VIPomas). ... Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Somatostatin and Analogues …

Bepotastine

Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available...
Approved
Matched Iupac: … 4-{4-[(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid …
Matched Description: … in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand ... It is available in oral and opthalmic dosage forms in Japan. ... The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve. …

Remimazolam

Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid...
Approved
Investigational
Matched Description: … thus susceptible to rapid biotransformation and elimination as inactive metabolites. ... Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation ... [A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

Valoctocogene roxaparvovec

Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector that expresses the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ). The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active...
Approved
Investigational
Matched Description: … [L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for ... hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and ... A252797] As opposed to these therapies, valoctocogene roxaparvovec offers the advantage of continuous and …
Matched Categories: … Cellular and Gene Therapy ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Tecovirimat

The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980. However, there have been longstanding concerns that smallpox may be used as a bioweapon.[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. It is effective against all orthopoxviruses,...
Approved
Investigational
Matched Description: … to treat monkeypox and cowpox in adults and children. ... [L40154] Tecovirimat is available as both oral and intravenous formulations.[L41835] ... The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, …

Daridorexant

Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Description: … Conventional treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), ... Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of ... associated with comorbidities such as hypertension, diabetes, and depression. …
Matched Categories: … Hypnotics and Sedatives …

Brexucabtagene autoleucel

Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib, the prognosis for MCL patients remains poor and those that relapse...
Approved
Matched Description: … ], the prognosis for MCL patients remains poor and those that relapse following BTK inhibitor therapy ... Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib ... therapies have been developed that modify a patient's own T cells using viral transduction to bind to and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic cell and gene therapy ... Receptors, Cytoplasmic and Nuclear ... Antineoplastic and Immunomodulating Agents …

Guselkumab

Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in...
Approved
Investigational
Matched Description: … In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …

Pegunigalsidase alfa

Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by the deficiency of alpha-galactosidase A.[A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as agalsidase alfa and agalsidase beta, pegunigalsidase alfa uses a...
Approved
Investigational
Matched Description: … allowing it to reach target organs with a lower dose and frequency of administration. ... [A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as [agalsidase alfa] and ... While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Clocortolone

Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.
Approved
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …

Trilostane

Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.
Approved
Investigational
Vet approved
Withdrawn
Matched Categories: … Sex Hormones and Insulins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Displaying drugs 676 - 700 of 15294 in total